Patient groups push back against Gilead's pricey HIV prevention treatment

"Descovy, shown to be less toxic than Truvada to the kidneys and bones in clinical trials, was approved in 2016 for people already infected with HIV. Advisers to the U.S. Food and Drug Administration will meet on Wednesday to decide whether to recommend Descovy for PrEP, with agency approval widely expected before the end of the year."

"HIV drugmakers have largely been shielded from generic competition. Each time one of their therapies came close to losing patent protection, scientific advances allowed them to introduce a new drug that improved on its predecessor, often with a higher price.

Both Truvada and Descovy are priced at $21,000 per year, before discounts provided to public and private health insurers. In the first half of 2019, Gilead’s Truvada sales totaled $1.3 billion. Descovy sales amounted to $700 million and are expected to rise to $3 billion dollars annually by 2024, according to IBES data from Refinitiv."